Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E6011 in PBC Inadequately Responding to UDCA
NCT03092765Phase 2Terminated
- Sponsor
- EA Pharma Co., Ltd.
- Start
- May 2017
- Primary completion
- Aug 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of quetmolimab in primary biliary cholangitis (PBC), sponsored by EA Pharma Co., Ltd.. Started May 2017; status: terminated.
02
Drugs
quetmolimab
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT03092765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03092765.